Myovant Sciences Drug Patent Portfolio

Myovant Sciences owns 1 orange book drug protected by 7 US patents Given below is the list of Myovant Sciences's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11793812 Methods of treating endometriosis 03 May, 2038
Active
US11033551 Methods of treating uterine fibroids 29 Sep, 2037
Active
US11957684 Treatment of heavy menstrual bleeding associated with uterine fibroids 29 Sep, 2037
Active
US11795178 Compositions of thienopyrimidine derivatives 27 Sep, 2033
Active
US7300935 Thienopyrimidine compounds and use thereof 28 Jan, 2025
Active
US8058280 Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof 28 Jan, 2025
Active
US9346822 Thienopyrimidine compounds and use thereof 17 Feb, 2024 Expired


Given below is the list of recent legal activities going on the following drug patents of Myovant Sciences.

Activity Date Patent Number
Patent litigations
Email Notification 17 Apr, 2024 US11957684
Mail Patent eGrant Notification 16 Apr, 2024 US11957684
Patent eGrant Notification 16 Apr, 2024 US11957684
Recordation of Patent Grant Mailed 16 Apr, 2024 US11957684
Patent Issue Date Used in PTA Calculation 16 Apr, 2024 US11957684
Recordation of Patent eGrant 16 Apr, 2024 US11957684
Email Notification 28 Mar, 2024 US11957684
Issue Notification Mailed 27 Mar, 2024 US11957684
Email Notification 14 Mar, 2024 US11957684
Mailing Corrected Notice of Allowability 14 Mar, 2024 US11957684
Dispatch to FDC 13 Mar, 2024 US11957684
Workflow - Request for RCE - Finish 13 Mar, 2024 US11957684
Information Disclosure Statement considered 11 Mar, 2024 US11957684
Corrected Notice of Allowability 11 Mar, 2024 US11957684
Pubs Case Remand to TC 05 Mar, 2024 US11957684


Myovant Sciences Drug Patents' Oppositions Filed in EPO

Myovant Sciences drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Dec 15, 2022, by Sandoz Ag. This opposition was filed on patent number EP17823018A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP17823018A Dec, 2022 SANDOZ AG Granted and Under Opposition


Myovant Sciences's Family Patents

Myovant Sciences drugs have patent protection in a total of 33 countries. It's US patent count contributes only to 20.4% of its total global patent coverage. Click below to unlock the full patent family tree.

Family Patents



Myovant Sciences Drug List

Given below is the complete list of Myovant Sciences's drugs and the patents protecting them.


1. Myfembree

Myfembree is protected by 7 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11793812 Methods of treating endometriosis 03 May, 2038
(13 years from now)
Active
US11033551 Methods of treating uterine fibroids 29 Sep, 2037
(12 years from now)
Active
US11957684 Treatment of heavy menstrual bleeding associated with uterine fibroids 29 Sep, 2037
(12 years from now)
Active
US11795178 Compositions of thienopyrimidine derivatives 27 Sep, 2033
(8 years from now)
Active
US7300935 Thienopyrimidine compounds and use thereof 28 Jan, 2025
(3 months from now)
Active
US8058280 Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof 28 Jan, 2025
(3 months from now)
Active
US9346822 Thienopyrimidine compounds and use thereof 17 Feb, 2024
(7 months ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Myfembree's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List